REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo trial hopes to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will take …
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:56 UTC
-
New combo therapy aims to outsmart tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer than pembrolizumab alone. The trial enrolls about 158 adults whose cancer has returned or spread and no longer responds to platinum chemot…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo attack on head and neck cancer shows promise in early trial
Disease control Recruiting nowThis early-phase study tests whether combining a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has come back or spread. About 24 adults with limited metastatic disease…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 22, 2026 14:02 UTC